Millennium: The Takeda Oncology Company Release: Clinical Data Presented on Orteronel (TAK-700) Without Steroids in Non-Metastatic Prostate Cancer

Published: Jun 04, 2012

CHICAGO--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced updated results from a phase 2 study of orteronel, a selective oral 17,20 lyase inhibitor, dosed without prednisone in patients with non-metastatic castration resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA). These data were presented in a poster discussion session at the annual meeting of the American Society of Clinical Oncology (ASCO), held June 1-5 in Chicago, Illinois.

Back to news